Driven by Geopolitical and Sporting Events, Predictive Market Industry Open Interest Surpasses $1 Billion for the First Time
BlockBeats News, March 16th, data shows that Polymarket's overall market share has risen from about 40% to 55%. The daily average trading volume in the U.S. political market reached $28.17 million, far exceeding sports ($1.32 million) and cryptocurrency markets ($44,000). Since its inception, Polymarket has collected a total of $2.19 million in fees, with an average weekly revenue of $730,000.
The Polymarket platform has created a total of 295,000 markets, but only 505 "supermarkets" contributed 47% of the total historical trading volume; the top 10 most popular markets accounted for 57% of the total trading volume.
At the same time, 67.7% of markets have a lifespan of less than seven days, with 63% having zero trading volume within 24 hours of creation. Pricing includes an emotion premium: for example, in the "WTI Crude Oil to Reach $100 by Month End" market, Polymarket's pricing has consistently exceeded the Chicago Mercantile Exchange (CME) options' implied probability by 10 to 30 percentage points, reflecting a greater impact from emotion-driven speculative capital.
The geopolitical-related market's trading volume share has surged from about 3% to a peak of 14%, validating its value as a real-time financial intelligence system.
某交易所 Ventures expects that the prediction market may evolve along three trajectories: 1) achieving price convergence through quantitative fund arbitrage; 2) being pegged to or bundled with RWAs (real-world assets) to generate asset synergy effects; 3) under regulatory influence, differentiating into compliant derivative channels and decentralized pricing hubs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
